Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
May 04, 2023 11:09 ET
|
Belite Bio, Inc
The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development...
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
April 25, 2023 16:30 ET
|
Belite Bio, Inc
Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time pointA continued trend of slowing expansion of autofluorescence...
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
April 11, 2023 09:00 ET
|
Belite Bio, Inc
Virtual event on Wednesday, May 3rd at 1:00 PM ET will feature key opinion leader Hendrik Scholl, M.D. from the University of Basel, Switzerland 18-month interim efficacy and safety data from Belite...
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
March 31, 2023 19:03 ET
|
Belite Bio, Inc
12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the...
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
March 31, 2023 12:57 ET
|
Belite Bio, Inc
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant...
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
November 18, 2022 08:00 ET
|
Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry...
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
October 20, 2022 08:00 ET
|
Belite Bio, Inc
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27th at 11 AM ET SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) --...
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
October 01, 2022 19:03 ET
|
Belite Bio, Inc
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time pointThe majority of the subjects showed stabilization of BCVA in at least one...
Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
September 23, 2022 08:00 ET
|
Belite Bio, Inc
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based...
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
September 16, 2022 08:00 ET
|
Belite Bio, Inc
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patientsA 2-year Phase 2...